10 Observations in Aurobindo Facility Inspection

FDA had 10 observations in its 12/11-12/22/2023 pre-approval inspection at Aurobindo Pharma’s new injectable facility in East Windsor, NJ. India’s Business Standard reports the company said in a regulatory filing that the observations were “procedural” and would be addressed within the stipulated time.

Read more